Epoetin alfa in critically ill patients [4]

New England Journal of Medicine

Volumn 357, Issue 24, 2007, Pages 2516-

  Cooke, Colin R ^a   Rubenfeld, Gordon D ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT ERYTHROPOIETIN;

CRITICALLY ILL PATIENT; FISHER EXACT TEST; HAZARD RATIO; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; SURVIVAL TIME; CRITICAL ILLNESS; KAPLAN MEIER METHOD; NOTE; PROPORTIONAL HAZARDS MODEL; STATISTICAL ANALYSIS;

CRITICAL ILLNESS; DATA INTERPRETATION, STATISTICAL; EPOETIN ALFA; HUMANS; KAPLAN-MEIERS ESTIMATE; PROPORTIONAL HAZARDS MODELS;

EID: 37249084627     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Leung KM, Elashoff RM, Afifi AA. Censoring issues in survival analysis. Annu Rev Public Health 1997;18:83-104.
2. Amato MBP, Barbas CSV, Medeiros DM, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998;338:347-54.
3. Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71.
4. Schoenfeld D. Survival methods, including those using competing risk analysis, are not appropriate for intensive care unit outcome studies. Crit Care 2006;10:103.